VEVYE
Growthcyclosporine ophthalmic solution
NDAOPHTHALMICSOLUTION
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
VEVYE (cyclosporine ophthalmic solution) is calcineurin inhibitors [moa]. First approved in 2023.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VEVYE is a calcineurin inhibitor ophthalmic solution approved in May 2023 for the treatment of dry eye disease. It works by suppressing ocular inflammation and modulating the immune response in the tear-producing glands. The drug is administered as eye drops and represents a newer formulation entry in the cyclosporine dry eye market.
Growth15.9 years to LOE
Early-stage growth product in a well-established market; teams are scaling promotional infrastructure and building awareness against entrenched competitors.
Mechanism of Action
Calcineurin Inhibitors
Pharmacologic Class:
Calcineurin Inhibitor Immunosuppressant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VEVYE positions you in a high-visibility launch effort within a multi-billion dollar therapeutic area with strong unmet need. Early-stage growth roles offer opportunity to establish brand positioning and market share against entrenched competitors, though the crowded dry eye landscape requires sophisticated segmentation and payer strategies.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.